Exchange: NASDAQ·Updated 06:42 PM EST
CNTX logo

CNTX Context Therapeutics Inc

$0.16
$0.0086
(5.10%)
Today
Closed $0.16
$0.00
(0.00%)
After Hours
Mkt Cap$14.7M
Vol1.12M

About CNTX

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
57

Bullish Sentiment

How do you feel about CNTX?

saad545
$CNTX I can’t explain the price action for the last 3 months. This stock should be at least at .75 to 1.25$ . But I learned a rule that when a genuine stock punished harshly, at one point , It will go up aggressively
1
13
buymoremakemore
$CNTX As we wait for Q3 earnings update next week… The best chance at a 100M+/1B dollar re-rating next year, one of two things needs to happen. 1. CTIM-76 needs to be tolerated at higher doses and continue to show dose proportional efficacy in Q3W dosing. 280 micrograms is the full dose in a 3+3 prime dose setup, which showed great tumor shrinkage in weekly dosing data. So, if CTIM-76 is tolerated in the 300/400 microgram range with 3 week dosing, we should see some serious tumor killing. Thankfully safety is very good so far, so higher doses isn’t much of a concern for safety. 2. CT-202 ideally needs to show efficacy for both high Nectin-4 expression cancers such as bladder and triple-negative breast, and low/medium Nectin-4 expression cancers such as colorectal, all three of which co-express TROP2, EFGR and HER2. Low/medium expressing Nectin-4 tumor cell killing is important to maximize and broaden the potential for Nectin-4 combo therapies with other ADCs that co-express tumor targets such as TROP2/HER2/EFGR. The amount of money to be made in combination therapies for at least 5 different types of drugs in Nectin-4/TROP2/HER2/EFGR ADCs indiscriminate of Nectin-4 co-expression level, as well as PD-1 therapies, and all the cancer indications that go along with them definitely will not go un-noticed. If colorectal data is good by itself, then CNTX or a third party will have incentive to pursue CT-202 as a combo therapy for TROP2, HER2 and EFGR ADCs in cancer indications where Nectin-4 primarily is expressed at low/medium levels. Nectin-4 ADCs struggle to be effective in this area, due to their weak durability, limiting them to highly expressed Nectin-4 cancer cells. An example of a cancer like this is NCLSC, which co-expresses HER2, and Nectin-4, but only 7% of the 55% total Nectin-4 expression is high expression, so Nectin-4 ADCs don’t deal with this. So, there is a lot of money to be made not competing with Nectin-4 ADCs in certain indications. If CT-202 only has good data for one or both of the high Nectin-4 expression cancers (Bladder, Triple-Negative Breast), then a CT-202 combo therapy with a HER2 ADC or a TROP2 ADC, and/or an anti PD-1 drug like keytruda is also still attractive, which would avoid serious side effects of Padcev Nectin-4 ADC. Also a combo therapy with Padcev or another MMAE or TOPO1 Nectin-4 ADC for dual tumor killing of the same target and/or triple TCE + ADC + PD-1 combo is still attractive too. Only being limited to high-expression Nectin-4 indication ADC combo therapies just won’t be nearly as lucrative and extensive in terms of the potential buyers/partners if medium/low expression Nectin-4 ADC target combo therapies are not also viable, but it doesn’t mean that CT-202 won’t stand out or won’t be moved forward to later trials as a monotherapy or combo therapy. One of these two outcomes should easily get them a PIPE offering with Martin’s VC connections, which would extend cash runway for a considerable amount of time and remove this cash overhang, and stock can also get re-rated that way.
11
Synkum
$CNTX additional insight by Martin: “Yesterday we shared updated Phase 1 data for CTIM-76, our CLDN6 x CD3 T cell engager, in platinum-resistant ovarian cancer. The women in this study had already been through a median of six prior lines of therapy, and most had received an antibody-drug conjugate. For patients this far into treatment, options are few and every month matters. With longer follow-up, median progression-free survival reached 5.6 months among patients treated at biologically active weekly doses. Behind every data point is a patient who chose to take part in early research so that future patients might have better options. To each of them and their families: thank you. Thank you also to our investigators, site staff and the Context team, whose care and persistence made this work possible. The data are early, and there is more to learn. Next we optimize every-three-week dosing and plan to start Phase 1b in Q1 2027.”
8
e999
$CNTX TCE has a very high potential for the future Stock prices are sad about this. I hope the company makes the public announcement and proceeds with the share buyback soon.
1
5
buymoremakemore
$CNTX Even if CNTX does an R/S nobody says they have to raise money right away. Theyll be safely compliant through the CT-202 readout, which could trigger a massive rerating, which could be a good time to raise. If they can show promising efficacy in heterogeneously Nectin-4 expressing cancers, which should have a low ORR bar, because nectin-4 ADCs absolutley dont do well with those. And with a low float, two big data readouts could get fun. Shorts would also be playing with fire shorting when catalysts get closer regardless of an R/S. But that's just me. im not mad about them doing an R/S. They have the catalysts unlike many of these commercial bio stocks that either need to buy new assets or have stellar growth to dig themselves out of a hole. TLDR: If a R/S is required, and they're smart, they will wait to see if they can jack up the share price on low float, if one or both of their readouts causes a rerating, before hitting ATM or PIPE. Alright good luck guys. If you feel so brave, average down. Hopefully some updates soon.
7
Wacala
$CNTX Inst. Own 58.62% with a target of 4.12 according to FinViz, It seems like a positive worth while stock to risk. Think about that!!! It's worth the risk for me.
7
buymoremakemore
$CNTX a majority of traders will finish tax loss harvesting this week. Especially with midterms on deck. Good news in the Q3 ER PR can send this upward and break this downtrend Im optimistic one or both readouts will be good next year. Martin’s venture capital experience has already lended itself well to get funding. Like when they got 100M in PIPE 2 years ago without any clinical data and simply just an IND. Not to mention potentially more insider buying like they did last year between $0.50 - $0.70. Many ways to skin this cat
7
e999
$CNTX $CNTX CNTX has no rs history, and individuals have bought back shares multiple times. Also, the clinical results from similar companies are relatively good. cntx declined in June due to the small number of patients and samples, and on top of that, because they tried the high-risk group first, it ended up like this. It is not a clinical failure; two clinical trials are being conducted properly, and a clinical site has been added recently. Now, cntx needs to mention it directly!!!
7
e999
$CNTX Since the first patient was dosed in CT-202 on September 9, four sites had been recruiting patients, and on October 8, two additional sites were added, bringing the total to six participating sites. The trial is still ongoing. It’s not as if the trial failed in June; it’s currently progressing normally. Yet it’s ridiculous that the clinical pipeline is being valued at almost zero right now..😂
7
investhedge
$CNTX Eli Lilly very positive news from today, achieving 79% cORR and 100% DCR! In ovarian cancer treatment, great development news for industry! While it has not direct impact on CNTX, since we’re in a different sub area (CLDN6, Claudin 6) vs FRa that Lilly is targeting The industry is heating up , it’s a fact, and TCE should be a clear winner if things go well
6
Wacala
$CNTX Ok guys, this is not looking pretty, but are we in for the long run or are we going to panic? I sincerely believe cntx has a good potential trail results and a good chance of at least getting back to above 3. If things go supper well, it might go much higher. , suggested a very interesting professional and well informed group that places a target of 5. It might take a little time, but let's hope for the best!!! This is my Sunday positive thought 😘
5
Wacala
$CNTX this is awesome: "Tumor reduction was observed across metastatic sites, including regression of 7 liver lesions in 4 patients (median −58%; range −16% to −100%)."
5
SpencerF
$CNTX I wonder what the limits are to naked shorting. Could the big boys turn this down to 10 cents on Monday or do they kind of have to keep it gradual? Maybe they’ll shoot for New Year’s Eve to be the grand final zero out?
1
1
SpencerF
$CNTX assuming big pharma ordered their hedge fund buddies to take this all the way to 0 in the name of keeping cancer around. Will naked shorting be able to fully zero it out? Or will the pesky cash at hand keep it a 5 cent stock for a while?
1
1
Synkum
$CNTX Unless the management decides to actively engage the investment community, small insider buys will not do anything. Marty is too quite for a ceo of a public company. There must be a reason. We just don’t know it.
2
Luckylaura
$CNTX doesnt look good at all, if they had anything valueble, management would have bought or done something.
2
LabPsycho
$CNTX Can you provide one example where the SEC has penalized an insider for buying shares of their company.?
2
claybridge
$CNTX brutal. Volume and candlesticks from the previous 3 trading sessions suggested a bottom, then bam...another leg down. They've got twice as much cash per share relative to market cap. Assets are worthless? Geeez...
2
SpencerF
$CNTX I’m such an idiot for holding. Literally nothing ever comes back from this kind of price action. Could salvage a few grand if I dumped but nah gonna hold till 0.00
1
LabPsycho
$CNTX So..hypothetical scenario - Lets say it gets to 11 cents...buy 100k shares...close eyes for 2-3months...is it more likely to be 25 cents or 5 cents or $3 after a R/S and you are down another 40% or so? It may get cheap enough where they do a PIPES / reverse merger gimmick and buy some other developed in China drug in phase 2 sending this up to $1? HOWL would be recent example.

Advertisement|Remove ads.